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ABSTRACT
Huntington’s disease (HD) is a neurodegenerative disorder characterized by chorea, 
behavioral disturbances and dementia, caused by a pathological expansion of the CAG 
trinucleotide in the HTT gene. Several patients have been recognized with the typical HD 
phenotype without the expected mutation. The objective of this study was to assess the 
occurrence of diseases such as Huntington’s disease-like 2 (HDL2), spinocerebellar ataxia 
(SCA) 1, SCA2, SCA3, SCA7, dentatorubral-pallidoluysian atrophy (DRPLA) and chorea-
acanthocytosis (ChAc) among 29 Brazilian patients with a HD-like phenotype. In the group 
analyzed, we found 3 patients with HDL2 and 2 patients with ChAc. The diagnosis was not 
reached in 79.3% of the patients. HDL2 was the main cause of the HD-like phenotype in 
the group analyzed, and is attributable to the African ancestry of this population. However, 
the etiology of the disease remains undetermined in the majority of the HD negative 
patients with HD-like phenotype.
Key words: Huntington’s disease, Huntington’s disease-like, chorea-acanthocytosis, 
Huntington’s disease-like 2.
Análise clínica e genética em 29 pacientes brasileiros com fenótipo doença de 
Huntington-símile
RESUMO
A doença de Huntington (DH) é uma doença neurodegenerativa caracterizada por 
coréia, alterações comportamentais e demência, causada por uma expansão patológica 
do trinucleotídeo CAG no gene HTT. Vários pacientes têm sido descritos com o 
fenótipo típico para a DH porém sem a mutação esperada. O objetivo deste estudo 
foi avaliar a ocorrência de doenças como doença de Huntington-símile 2 (DHS-2), 
ataxias espinocerebelares tipo 1, 2, 3 e 17, atrofia dentatorubral-palidoluisiana e coreo-
acantocitose (CAc) entre 29 pacientes brasileiros com fenótipo doença de Huntington-
símile. No grupo analisado, encontramos 3 pacientes com DHS-2 e 2 pacientes com 
CAc. O diagnóstico permaneceu obscuro em 79,3% dos pacientes. DHS-2 foi a principal 
causa do fenótipo DH-símile no grupo analisado, provavelmente devido a ancestralidade 
africana na população brasileira. Entretanto, a etiologia permaneceu indeterminada na 
maioria dos pacientes avaliados.
Palavras-chave: doença de Huntington, doença de Huntington-símile, coreo-acantocitose, 
doença de Huntington-símile 2. 
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Huntington’s disease (HD) is a progressive, neurode-
generative disorder characterized by chorea, dystonia or 
parkinsonism, cognitive impairment and behavioral ab-
normalities, with typical onset in young adulthood. HD 
is caused by a pathological expansion of CAG trinucleo-
tide repeats in the HTT gene. 
Since the identification of the causative mutation, it 
has been recognized that a number of patients with the 
classical HD phenotype have disease due to another eti-
ology. These include prion diseases such as HDL1; auto-
somal dominant disorders due to inheritance of an ex-
panded trinucleotide repeat sequence, such as HDL2, 
and DRPLA (dentatorubral-pallidoluysian atrophy); 
disorders affecting primarily the cerebellum, in which 
movements disorders can also be seen - FRDA (Fried-
reich ataxia), SCA (spinocerebellar atrophy) 1, SCA 2, 
SCA 3 and SCA 17; the neuroacanthocytosis syndromes, 
chorea-acanthocytosis (ChAc) and McLeod syndrome; 
and the neurodegeneration with brain iron accumula-
tion (NBIA) syndromes, neuroferritinopathy, acerulo-
plasminemia and Pantothenate kinase-associated neu-
rodegeneration (PKAN). 
There have been several published studies addressing 
the etiological diagnosis of patients with an HD-like phe-
notype1-14; however, these have been mainly drawn from 
European and North American populations. We per-
formed a transversal study of the genetic and clinical 
findings from a group of non-HD HD-like patients who 
attended a Brazilian movement disorders clinic. 
METHOD
The medical records of 108 patients who were tested 
for HD between 1998 and 2006, were reviewed. Patients 
with an HD-like phenotype, defined as a progressive dis-
order with chorea, dystonia, parkinsonism, ataxia or my-
oclonus associated with a cognitive, psychiatric or be-
havioral impairment who did not have a pathological 
expansion on HTT gene underwent further clinical ex-
amination and testing for DRPLA, HDL2, SCA 1, 2, 3, 17 
and ChAc. Although a true HD-like phenotype requires 
autosomal dominant inheritance, we did not use this cri-
terion to select our patients, as an absent family history 
is non-informative. 
DNA analysis of ATN1 (DRPLA), JPH3 (HDL2), 
ATX1 (SCA1), ATX2 (SCA2), ATX3 (SCA3) and TBP 
(SCA17) were performed by sizing of fluorescent PCR 
products encompassing the CTG/CAG expansion site. 
The PCR products were loaded on 3730 DNA Analyzer 
or Megabace 1000 (GE) and analyzed using GeneMapper 
software [AppliedBiosystems] or Fragment Profiler (GE). 
As the standard PCR protocol does not allow detection 
of alleles carrying very large expansions as described for 
the juvenile, severe form of HD, triplet repeat primed 
PCR15, which permits detection of large expansions, was 
performed for all patients who were not heterozygous at 
the HTT locus and/or the JPH3 locus. 
Patients who were found to have acanthocytes on 
peripheral blood smear, elevation of serum CK levels, 
or evidence of myopathy or peripheral neuropathy, had 
Table 1. Clinical and molecular findings in HD and HDL patients.
HD HDL p
Number of cases 37 29
Age of onset 35.1±12.8 30.7±17.6 0.25†
Male:Female ratio 16:21 14:15 0.68‡
Chorea 37 (100%) 22 (75%) 0.002#
Ataxia 7 (18.9%) 8 (27.5%) 0.40‡
Myoclonus 0 2 (6.8%) 0.19#
Dystonia* 0 2 (6.8%) 0.19#
Tremor 0 1 (3.4%) 0.43#
Parkinsonism* 0 0 –
Psychiatric disturbance 17 (45.9%) 15 (51.7%) 0.64‡
Dementia 25 (65.7%) 20 (68.9%) 0.90‡
Epilepsy 4 (10.8%) 4 (13.7%) 0.72#
Familiar history 34 (91.8%) 
AD:34
19 (65.5%) 
AD: 14 (48.2%)
non-AD: 5 (17.2%)
0.007‡
htt CAG range 37-87 15-27 
HD: Huntington’s disease; HDL: Huntington’s disease-like; AD: autosomal dominant; *Dystonia or parkinsonism as a 
predominant manifestation; †Student’s t test; ‡χ2 test; #Fisher’s exact test.
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chorein levels in peripheral blood qualitatively analyzed 
by Western blot16 (n=2).
Statistical analysis was performed with SPSS version 
10.0 (SPSS, Inc., Chicago, IL, USA). This study was ap-
proved by the ethical board of the Hospital das Clínicas 
de Ribeirão Preto and all patients have signed an in-
formed consent. 
RESULTS
Of the 108 patients tested for HD, seven were ex-
cluded due to insufficient data in their medical records. 
From the remaining subjects, 37 were diagnosed with 
HD, 35 were not classified as having an HD-like pheno-
type, and 29 were classified as a HD-like phenotype. As 
a result, considering the patients with a typical or com-
patible HD phenotype, we found 29/66 patients (43%) 
without pathological CAG expansion on HTT gene. 
Table 1 summarizes the main clinical features of HD 
and HD-like patients. MRI exams were performed in 24 
patients and brain CT in 3. The most common finding 
was brain atrophy in 23 (85%) patients. We found no ev-
idence of iron deposition on those patients who under-
went MRI exams. All 29 HDL patients had their DNA 
analyzed for trinucleotide repeat expansions of HTT, 
JPH3, ATX1, ATX2, ATX3, TBP and ATN1. Two pa-
tients met criteria for chorein testing and had absent or 
markedly reduced levels in peripheral blood. From these 
tests, we diagnosed 3 (10.3%) cases of HDL2 and 2 (6.8%) 
Table 2. Review of HD-like screening studies.
Year Reference Population Nº HDL Evaluation Results
1998 1 US and UK 15 SCA 1,2,3,6 and DRPLA 0
2000 2 European
(France)
32 SCA 1,2,3,6,7, DRPLA
RED test
1 patient with an unknown 
CAG expansion 
2001 3 American
(African ancestry)
330 HDL2 4 HDL2 
2002 4 European
(Germany and Austria)
1600 HDL2 0
2003 5 European
(France)
252 HDL 1, HDL2, SCA 17 
and DRPLA
HDL2 = 2 (3.3% of typical cases)
SCA 17 = 2 (3.3% of typical cases) 
2004 6 European
(Germany and Austria)
1712 SCA 17 9 (0.005%)
2004 7 (North America 
Japan, Mexico)
538 (NA) and 
44 (Japan)
HDL2 North America 6/538 (1.1%)
Japan 0/44
2004 8 European
(Italy)
98 SCA 17. HDL2 
previously excluded
1 possible case with 
43 repetitions
2005 9 European
(Yugoslav)
48 HDL1, HDL2, 
SCA 1,2,3,17, DRPLA, NFP
0
2005 10 African
(South Africa)
50 HDL2 15 (30%)
2006 11 European
(Portugal)
107 HDL1, HDL2, SCA 17, 
DRPLA, NFP
0
2008 12 European
(Spain)
95 FXTAS 1 (1.6%)
2008 13 European
(UK)
285 HDL1, HDL2, 
SCA 1,2,3,17, DRPLA, 
NFP, FRDA
SCA 17 = 5 (1.8%)
HDL1 = 1 (0.4%)
FRDA = 1 (0.4%)
HDL2 = 1 (0.4%)
2008 14 European
(Polish)
224 HDL2, SCA17, DRPLA SCA 17= 1 (0.44%)
2011 Brazilian 29 HDL2, SCA 1,2,3,17, 
DRPLA, ChAc
HDL2 = 3 (10.3%)
ChAc = 2 (6.8%)
HDL: Huntington’s disease-like; DRPLA: dentatorubral-pallidoluysian atrophy; FRDA: Friedreich ataxia; SCA: spinocerebellar atrophy; ChAc: chorea-
acanthocytosis; NFP: neuroferritinopathy; FXTAS: Fragile X–associated tremor/ataxia syndrome; RED: repeat expansion detection technique.
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cases of ChAc. The patients with HDL2 were clinically 
indistinguishable from those with typical HD pheno-
type. However, patients with ChAc presented clear clin-
ical differences as absence of autosomal dominant his-
tory, presence of peripheral involvement and epilepsy in 
both cases. The patients with HDL2 and ChAc have been 
previously reported in detail elsewhere17,18.
One patient of this study was a deceased sister of 
one ChAc patient, who presented with chorea and cog-
nitive abnormalities, but whose diagnosis could not be 
confirmed by Western blot due to the non-availability 
of required biomaterial. The remaining 23 (79.3%) pa-
tients tested negative for HD, HDL2, SCA1, 2, 3, 17, and 
DRPLA. 
DISCUSSION
This is the first study to address the diagnosis of dis-
eases responsible for the HD-phenotype in Brazilian pa-
tients. Compared with previous studies (Table 2), we 
found a higher frequency of ChAc and HDL2 among our 
patients. Considering the 3 unrelated HDL2 cases re-
ported here, together with the patients reported by Teive 
et al.19 and Santos et al.20, it is possible that HDL2 is the 
most common cause of HD-like phenotype in Brazil. A 
probable explanation is that 44% of Brazilian population 
is of African descent21, even though this ancestry may be 
occult19,20. This regional difference contrasts with the ar-
ticle of Wild and colleagues13, in which SCA 17 was con-
sidered the most important cause of the HD-like pheno-
type in patients from the UK. 
Based upon previous studies, we initially decided to 
test for disorders whose frequencies were higher than 
0.5% of all HD phenocopies. Consequently, we included 
SCA 17 and HDL2 and excluded HDL1 and FRDA13. We 
have not included neuroferritinopathy because it appears 
to be even rarer in HD-like patients, with a very small 
number of families being reported to date, and it is un-
likely to occur in patients without evidence of iron de-
position in the basal ganglia on MRI22. 
Screening for ChAc was performed as the clinical 
characteristics of our patients suggested the diagnosis. 
It was important to include the investigation for ChAc 
because Brazil represents the largest population of Jap-
anese and descendants outside Japan21, and ChAc ap-
pears to be particularly prevalent in Japanese subjects23. 
DRPLA was included for the same reason. In addition, 
studies have demonstrated that the number of DRPLA 
cases in non-Asian populations may be higher than pre-
viously considered24,25. Finally, chorea has been reported 
as an occasional non-ataxic symptom on SCAs, occur-
ring in approximately 7% of SCA 1 and 2 and 10% of SCA 
3 patients26. 
Our data showed that almost 43% of the patients 
who had a phenotype compatible with HD tested nega-
tive for CAG expansions at the HTT gene. This data di-
verges from reference studies in this field, which suggest 
that the frequency of HD-like phenocopies is about 1% 
of HD cases27,28. We believe that this discrepancy cannot 
be addressed only as an ascertainment bias, because our 
sample was selected based on restrictive criteria. In ad-
dition, other studies have found proportions of HD-like 
patients in 33%10, 35.5%11, and 36.3%9 of their study pop-
ulations. Krause and colleagues10 provided an insight in 
this problem, showing that, in their population, only 16% 
of white patients were HD phenocopies, in contrast to 
64% of the black patients. Therefore, the percentage of 
HD-like patients may differ according to the ethnicity of 
the study population. 
Our clinical data shows that the absence of an auto-
somal-dominant history and signs of peripheral involve-
ment or seizures may help differentiate between ChAc 
and HD. Although the presence of acanthocytes may im-
prove the diagnostic accuracy, their absence does not 
rule out the diagnosis of ChAc29. In addition to screening 
for acanthocytes, we considered the diagnosis of ChAc 
in patients with elevated CK levels and clinical signs of 
myopathy or peripheral neuropathy. 
The patients with HDL2 were clinically very similar 
to the classical HD phenotype, and this diagnosis should 
be suspected in the presence of typical HD phenotype 
with absent HTT mutation, especially if an autosomal 
dominant inheritance and African ancestry is present.
However, this survey has some limitations. First, the 
small number of patients identified as having an HD-like 
phenotype, what can be explained by the rarity of these 
disorders and because we have enrolled patients from 
only one clinical center. Second, referral bias is unavoid-
able when including patients from a referral movement 
disorders clinic, therefore, it is possible that the relative 
frequency of HD-like disorders was overestimated. Third, 
in spite of screening systematically for seven diseases, 
79.3% of our patients remained undiagnosed, confirming 
a considerable etiologic heterogeneity among HD-like 
disorders and indicate the need for additional studies, 
using a broader panel of diagnostic tests. Considering the 
discrepancy between the high percentage of cryptic cases 
and the rareness of the remaining diseases to be tested 
for, it is likely that among the HD-like phenotypes some 
causalities have not been described yet.
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